EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Psilocybin as a novel treatment for chronic pain

Tate Askey, Reena Lasrado, Maria Maiarú iD, Gary J Stephens iD

British Journal of Pharmacology · 2026-07 · 183 (14) · 3992-4005

DOI: 10.1111/bph.17420 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-11-29. Written by Tate Askey and 3 co-authors. Institution: Department of Pharmacology, School of Pharmacy, University of Reading, Reading, RG6 6UB, UK. Major MEDLINE topics: Psilocybin, Chronic Pain, Hallucinogens, Analgesics. Cited 16 times so far (Crossref); 114 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain. This review primarily explores the utility of preclinical animal models in investigating the potential of psilocybin as an anti‐nociceptive agent. Initial studies involving psilocybin in animal models of neuropathic and inflammatory pain are summarised, alongside areas where further research is needed. The potential mechanisms of action, including targeting serotonergic pathways through the activation of 5‐HT 2A receptors at both spinal and central levels, as well as neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain, are considered. Current clinical aspects and the translational potential of psilocybin from animal models to chronic pain patients are reviewed. Also discussed is psilocybin's profile as an ideal anti‐nociceptive agent, with a wide range of effects against chronic pain and its associated inflammatory or emotional components. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc

Subjects

MeSH terms (MEDLINE)

PsilocybinChronic PainHallucinogensAnalgesicsHumansAnimals

Author keywords

neuropathic painneuroplasticitynociplastic painpsilocybinpsychedelic drugsserotonergic signalling

Substances

PsilocybinHallucinogensAnalgesics

Authors and institutions

  • Department of Pharmacology, School of Pharmacy, University of Reading, Reading, RG6 6UB, UK.
  • Compass Pathways, London, W1F 0DQ, UK.

ORCID profiles: Maria Maiarú, Gary J Stephens

Cite

APA

Askey, T., Lasrado, R., Maiarú, M., & Stephens, G. J. (2026). Psilocybin as a novel treatment for chronic pain. British Journal of Pharmacology, 183(14), 3992-4005. https://doi.org/10.1111/bph.17420

Vancouver

Askey T, Lasrado R, Maiarú M, Stephens GJ. Psilocybin as a novel treatment for chronic pain. British Journal of Pharmacology. 2026;183(14):3992-4005. doi:10.1111/bph.17420

BibTeX
@article{Askey2026,
  author = {Askey, Tate and Lasrado, Reena and Maiarú, Maria and Stephens, Gary J},
  title = {Psilocybin as a novel treatment for chronic pain},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {14},
  pages = {3992--4005},
  doi = {10.1111/bph.17420}
}
Start for free →